Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

NCT04335591 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometriosis

Interventions

DRUG: 75 mg linzagolix tablet
DRUG: 200 mg linzagolix tablet
DRUG: Placebo tablet to match 75 mg linzagolix tablet
DRUG: Placebo tablet to match 200 mg linzagolix tablet
DRUG: Add-back capsule (E2 1 mg / NETA 0.5 mg)
DRUG: Placebo capsule to match Add-back capsule

Sponsor

Kissei Pharmaceutical Co., Ltd.